ANTIMICROBIAL RESISTANCE SOLUTIONS
WITH DR. JOHN H. REX
Latest Newsletters
Dear All (Deeply wonkish alert! Settle in! Great stuff here!):For today, we have a deep dive into the ongoing work in the EU to develop a set of realistic pull incentives using our best understanding to date of realistic choices. If the idea of Pull (and Push) is new to you, please check out this high-level written explainer or this YouTube explainer. And if you are already fluent in Push-Pull, the 13 April 2025 newsletter (“Most current global summary of Pull incentives”) might be of interest.With respect to the EU’s initiatives, you will hopefully know that the EU have been working towards Pull incentives. As background, here a few places to start reading: 2 May 2023 newsletter: “European Commission: Proposed Pull incentives!” This one provides a good overview of the initial TEV-based structure. 4 Dec 2023 newsletter: “Pan-EU/EEA Pull incentive: A proposal by DRIVE-AB alumni!” This one advances the conversation by describing a flexible revenue guarantee that could work for Europe. And these two cover the UK’s model: 8 May 2024 newsletter: “New UK 5-year AMR plan: Subscription model details!” 19 Aug 2024 newsletter: “UK Subscription model goes live! Value bands cover entire UK!” To add to this, we have...
Dear All,Attention phage developers --...
Dear All,D-Day and the momentous Normandy...
Latest Government Action
Dear All (Deeply wonkish alert! Settle in! Great stuff here!):For today, we have a deep dive into the ongoing work in the EU to develop a set of realistic pull incentives using our best understanding to date of realistic choices. If the idea of Pull (and Push) is new to you, please check out this high-level written explainer or this YouTube explainer. And if you are already fluent in Push-Pull, the 13 April 2025 newsletter (“Most current global summary of Pull incentives”) might be of interest.With respect to the EU’s initiatives, you will hopefully know that the EU have been working towards Pull incentives. As background, here a few places to start reading: 2 May 2023 newsletter: “European Commission: Proposed Pull incentives!” This one provides a good overview of the initial TEV-based structure. 4 Dec 2023 newsletter: “Pan-EU/EEA Pull incentive: A proposal by DRIVE-AB alumni!” This one advances the conversation by describing a flexible revenue guarantee that could work for Europe. And these two cover the UK’s model: 8 May 2024 newsletter: “New UK 5-year AMR plan: Subscription model details!” 19 Aug 2024 newsletter: “UK Subscription model goes live! Value bands cover entire UK!” To add to this, we have...
Dear All,Attention phage developers --...
Dear All,D-Day and the momentous Normandy...
Dear All,If you represent a...
Dear All, Sadly, I must...
Dear All (and with thanks...
Dear All, The Global Leaders Group on Antimicrobial...
R&D Insight
Dear All:FDA’s approval of delafloxacin...
Dear All: GARDP and CARB-Xed co-sponorsored yesterday an...
Dear All,Our colleagues at FDA...
See also This related newsletter:...
Can you help?
Dear All,I have just learned that Lifeline, the musical formerly known as The Mould that Changed the World, is seeking scientists, medics, and healthcare professionals to be part of the cast for a portion of a planned 5-week off-Broadway run of the show around the time of the High-Level Meeting (HLM) on AMR at UNGA 2024 in New York City...
Dear All, Heads up! Having...
Note: Be sure to take...
Update on 11 October 2023:Â The...
Dear All,Along with more than...
Dear All (and with thanks to...
Dear All, Two items for...
Dear All, Three things today......
Dear All, Greetings from ECCMID...
Dear All,A key theme of...
Dear All,Following hard on the...
Dear All, A short one...
Dear All, We are swimming...
Antimicrobial resistance poses a catastrophic threat. If we don’t act now, any one of us could go into hospital in 20 years for minor surgery and die because of an ordinary infection that can’t be treated by antibiotics. And routine operations like hip replacements or organ transplants could be deadly because of the risk of infection.
AMR Fireside Chats
1/18 videos
1
Episode 17 w/ Ella Balasa and Rob Purdie of WHO Task Force of AMR Survivors - AMR Fireside Chat
38:24
2
Episode 16 w/ Ramanan Laxminarayan, PhD - AMR Fireside Chat
32:59
3
Episode 15 w/ Mark Albrecht, PhD - AMR Fireside Chat
43:55
4
Episode 14 w/ Lynn Silver - AMR Fireside Chat
56:23
5
Episode 13 w/ Kevin Outterson - AMR Fireside Chat
30:01
6
Episode 12 w/ Tina Joshi, PhD - AMR Fireside Chat
34:22
7
Episode 11 w/ Martin Heidecker - AMR Fireside Chat
32:31
8
Episode 10 w/ Anna Govett - AMR Fireside Chat
14:54
9
Episode 9 w/ Fatema Rafiqi, PhD - AMR Fireside Chat
34:10
10
Episode 8 w/ Ghada Zoubiane, PhD - AMR Fireside Chat
35:04
11
Episode 7 w/ Trevor Lithgow, PhD - AMR Fireside Chat
35:41
12
AMR Snapshots: Episode 2 - John Rex (Editor-In-Chief, AMR.Solutions)
26:25
13
Episode 6 w/ Maryn McKenna - AMR Fireside Chat
45:50
14
Episode 5 w/ Christine Ă…rdal - AMR Fireside Chat
43:44
15
Episode 4 w/ Peter Beyer - AMR Fireside Chat
39:21
16
Episode 3 w/ Kevin Outterson - AMR Fireside Chat
11:45
17
Episode 2 w/ Henry Skinner, PhD - AMR Fireside Chat
15:44
18
Episode 1 w/ Kevin Outterson - AMR Fireside Chat
52:56
Non-traditional antibiotics: A pipeline review and an analysis of key development challenges
Dear All, Non-traditional alternatives to antibiotics have excited a lot of interest in the past few years but we’ve seen relatively few of these progress ...
Read More →
FDA Workshop: Animal models in support of narrow-spectrum agents for A. baumannii and P. aeruginosa
Dear All: FDA today hosted their eagerly awaited workshop on animal models in support of narrow-spectrum agents for A. baumannii (Abau) and P. aeruginosa (Pae). It was a really ...
Read More →
Developing antibiotics for children: There are no easy answers
Aside: If you’ve enjoyed the prior discussions of movies to inspire antibiotic R&DÂ and very apropos given the theme of today’s newsletter, please check out the ...
Read More →
Plazomicin (Achaogen) financial post-mortem: #PassPASTEUR
Dear All (and with thanks to Kevin for co-authoring and also a wonkish alert … get your coffee and settle in for the details), If ...
Read More →
Global survey of novel antibiotic reimbursement models / PASTEUR Act introduced to US House
Dear All (wonkish alert, but the details are fascinating … and with thanks to Kevin Outterson for co-authoring!), Two related items of note for today. ...
Read More →
Draft EMA antibacterial guidance: Analysis
Dear All: I wrote previously that EMA posted an extensively updated and consolidated version of their previously separate Guideline (CPMP/EWP/558/95 Rev.2) and Addendum (EMA/CHMP/351889/2013) documents into a single draft ...
Read More →
New pipeline analysis: Cancer projects were funded 17x more than antibacterials during 2011-2020
Dear All (wonkish alert: coffee up, settle in, and read the reports!), As you will recall, WHO’s most current pipeline review found that globally we ...
Read More →
Chemical vs. drugs (Part 2): How do you discriminate? / More on halicin
This newsletter is part of a series — here are the links to Part 1, (this one is Part 2), Part 3, Part 4, and Part 5. Also relevant ...
Read More →
Modeling the value of an effective antibiotic — Megiddo et al.
Dear All: I have previously written about the challenge of applying health technology assessment (HTA) to estimate the monetary value of an effective antibiotic: To my knowledge, ...
Read More →
Mirror Bacteria: An AMR threat of unprecedented magnitude
Dear All (wonkish but stick with it … I’m going to try very hard to de-wonk it), In an absolutely terrifying paper and technical report ...
Read More →
What does an antibiotic cost to develop? What is it worth? How to afford it?
Dear All (long, wonkish note alert!): Today we have a 3-part discussion of cost and value with this summary 3-part message: Developing antibiotics is expensive, ...
Read More →
Scary, Scarier, Scariest (Part 2): What can YOU do about it?
Long note alert— apologies! Get a cup of coffee and settle in… Dear All: My 22 Apr 2019 note entitled Scary, Scarier, Scariest: Achaogen / FT ...
Read More →
The thoughtless person playing with penicillin treatment is morally responsible for the death of the man who succumbs to infection with the penicillin-resistant organism.
The bipartisan PASTEUR Act is the strongest bill ever written to strengthen antibiotic development and use. It will fix our market failures, expand the pipeline for next generation antibiotics, and save lives. We can’t sit on our hands as this public health crisis arrives – we have to act now.
Summaries
Notes: Newsflash ... BARDA have...
Aside: If you've enjoyed the...
See also This related newsletter:...
Dear All (and with thanks...
Dear All (Wonkish alert! Coffee-up!),Today...